文献速递妇科

宫颈癌科学现状:从血管生成阻断到检查点抑制

Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
PubMed 文献 · Gynecol Oncol · 2018-02-03

综述阐述血管内皮生长因子(VEGF)靶向治疗在宫颈癌中的发展,贝伐珠单抗联合化疗成为复发/转移性宫颈癌一线治疗,基于GOG 240试验的总生存改善(17.0 vs 13.3个月;HR 0.71;98% CI 0.54-0.95;p=.004)。免疫检查点抑制剂针对PD-1/PD-L1通路的研究正在进行,包括II期纳武利尤单抗和帕博利珠单抗研究及III期GOG 3016(西米普利单抗)。

要点

  • 贝伐珠单抗联合化疗为复发/转移性宫颈癌一线治疗,基于GOG 240试验总生存改善。
  • GOG 240最终分析显示持续生存曲线分离 favoring VEGF抑制:16.8 vs 13.3个月;HR 0.77;95% CI 0.62-9.95;p=.007。
  • 贝伐珠单抗相关阴道瘘均发生于既往盆腔放疗者,无急诊手术、脓毒症或死亡。

核心结论

  • 贝伐珠单抗联合化疗已成为复发/转移性宫颈癌一线治疗,基于GOG 240试验的统计显著且临床有意义的生存改善。
  • 免疫检查点抑制剂针对PD-1/PD-L1通路在宫颈癌中的研究正在进行,包括II期和III期试验。

研究设计与样本

  • 综述,总结宫颈癌从血管生成阻断到检查点抑制的科学现状,引用GOG 240 III期随机试验等证据。

主要发现

  • GOG 240试验显示贝伐珠单抗联合化疗较单纯化疗改善总生存:17.0 vs 13.3个月;HR 0.71;98% CI 0.54-0.95;p=.004。
  • 贝伐珠单抗联合化疗显著改善无进展生存和缓解,且不伴生活质量恶化。
  • GOG 240最终方案指定分析显示持续生存曲线分离 favoring VEGF抑制:16.8 vs 13.3个月;HR 0.77;95% CI 0.62-9.95;p=.007。
  • GOG 240中两组进展后生存无显著差异。
  • 贝伐珠单抗相关阴道瘘均发生于既往盆腔放疗者,无一导致急诊手术、脓毒症或死亡。

关键数值与推荐

  • GOG 240:贝伐珠单抗联合化疗组总生存17.0个月 vs 单纯化疗组13.3个月;HR 0.71;98% CI 0.54-0.95;p=.004。
  • GOG 240最终分析:贝伐珠单抗联合化疗组总生存16.8个月 vs 单纯化疗组13.3个月;HR 0.77;95% CI 0.62-9.95;p=.007。

临床怎么用

  • 贝伐珠单抗联合化疗双药方案为复发/转移性宫颈癌女性一线治疗。
  • 免疫检查点抑制剂在宫颈癌中的II期研究(纳武利尤单抗、帕博利珠单抗)正在进行,III期GOG 3016(西米普利单抗)近期启动。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic cervical carcinoma. Regulatory approval for this indication was based on the phase III randomized trial, GOG 240, which demonstrated a statistically significant and clinically meaningful improvement in overall survival when bevacizumab was added to chemotherapy: 17.0 vs 13.3 months; HR 0.71; 98% CI, 0.54-0.95; p = .004. Incorporation of bevacizumab resulted in significant improvements in progression-free survival and response. These benefits were not accompanied by deterioration in quality of life. GOG 240 identified vaginal fistula as a new adverse event associated with bevacizumab use. All fistulas occurred in women who had received prior pelvic radiotherapy, and none resulted in emergency surgery, sepsis, or death. Final protocol-specified analysis demonstrated continued separation of the survival curves favoring VEGF inhibition: 16.8 vs 13.3 months; HR 0.77; 95% CI, 0.62-9.95; p = .007. Post-progression survival was not significantly different between the arms in GOG 240. Moving forward, immunotherapy has now entered the clinical trial arena to address the high unmet clinical need for effective and tolerable second line therapies in this patient population. Targeting the programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) pathway using checkpoint inhibitors to break immunologic tolerance is promising. The immunologic landscape involving human papillomavirus-positive head and neck carcinoma and cutaneous squamous cell carcinoma can be informative when considering feasibility of checkpoint blockade in advanced cervical cancer. Phase II studies using anti-PD-1 molecules, nivolumab and pembrolizumab are ongoing, and GOG 3016, the first phase III randomized trial of a checkpoint inhibitor (cemiplimab) in cervical cancer, recently activated. Important considerations in attempts to inhibit the inhibitors include pseudoprogression and post-progression survival, abscopal effects, and immune-related adverse events, including endocrinopathies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018. PMID: 29666026. doi:10.1016/j.ygyno.2018.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。